Comentario: Neurotoxicity due to monoclonal antibodies
Thank you very much for your comment on our poster. Monoclonal antibody therapy has revolutionized the field of many diseases since the first study carried out by Kholer and Milstein, research that earned them the Nobel Prize in Medicine.
All therapy carries risks and benefits, it depends on the individual evaluation of each patient as well as medical experience, seeking the best option for each patient.
However, in the field of Oncology it has been a very encouraging therapeutic option, when other therapies do not achieve the expected results. Various studies comment on the need for early use of immunotherapy, and not for it to be used as a last option.
Thank you for your interest in our poster.
Osvaldo Aguilera Batista Universidad de Ciencias Médicas de HolguÃn (2024-06-05)
En respuesta a Neurotoxicity due to monoclonal antibodies